New research is shedding light on a surprising connection between breast cancer treatment and the risk of developing Alzheimer’s disease. According to a large-scale study conducted by Korean scientists, women who have survived breast cancer may be less likely to develop Alzheimer’s dementia than those without a history of the disease. This finding offers a new perspective on the long-term health impacts of cancer treatment, particularly radiation therapy, and could influence how we think about cognitive health in aging populations.

The study, which evaluated health records from over 70,000 women treated for breast cancer between 2010 and 2016, compared these survivors to a control group of approximately 180,000 women without breast cancer. Over an average follow-up period of 7.3 years, 1,229 of the breast cancer survivors were diagnosed with Alzheimer’s. Researchers found that, overall, these survivors had an 8% lower risk of developing the disease. This protective effect was especially notable among women who were diagnosed with breast cancer at age 65 or older.

One of the most intriguing aspects of the study was the role of radiation therapy. Often used after surgery to eliminate residual cancer cells and reduce recurrence, radiation therapy was associated with a 23% lower risk of Alzheimer’s among those who received it. This finding surprised the researchers, especially given the common concern about cognitive decline following cancer treatments, a phenomenon often referred to as “chemo brain.”

“Concerns about chemo brain and the long-term adverse effects of breast cancer treatment on cognition are common, but our findings suggest this treatment does not directly lead to [Alzheimer’s disease],” the study authors wrote. I found this detail striking, as it challenges a prevailing narrative about the cognitive side effects of cancer therapy and suggests a more nuanced picture.

While radiation therapy appeared to be the most protective, the study did not find significant links between Alzheimer’s risk and other common breast cancer treatments such as chemotherapy or hormone therapy. This distinction may help guide future research into how specific treatments influence brain health over time.

The researchers also referenced earlier studies that proposed certain breast cancer therapies might reduce the buildup of amyloid-beta and tau proteins in the brain — both of which are key markers of Alzheimer’s disease. Although this study did not directly measure those proteins, the association adds a layer of biological plausibility to the findings.

However, the study’s authors were careful to acknowledge its limitations. They noted that data on the stage of breast cancer and the dosage of radiation therapy was not available, which could influence outcomes. Additionally, because the study focused on patients with operable breast cancer, the results may not apply to older individuals with advanced-stage disease or significant comorbidities.

Another important caveat is the duration of the protective effect. The researchers observed that the lower risk of Alzheimer’s did not extend beyond five years following treatment. “Based on these findings, we hypothesize that the risk of AD could be lowered shortly after cancer treatment but may equalize as the survival period increases,” they wrote. This suggests that any cognitive protection conferred by treatment may be temporary, and long-term surveillance remains important.

It’s also worth noting that the maximum follow-up period in the study was 11 years. Given that Alzheimer’s disease often develops slowly over decades, the researchers emphasized the need for longer-term studies to better understand how breast cancer treatment may influence dementia risk over time.

In the broader context, these findings intersect with two major public health challenges. Breast cancer remains one of the most common cancers among women in the United States, with one in eight women expected to be diagnosed in their lifetime. Meanwhile, Alzheimer’s disease continues to rise in prevalence, disproportionately affecting women, who represent nearly two-thirds of all cases. The Alzheimer’s Association projects that the number of Americans living with the disease will double by 2060, reaching an estimated 14 million adults.

While there is currently no cure for Alzheimer’s, early detection and treatment can help manage symptoms and potentially slow progression. Understanding how other health conditions and treatments interact with Alzheimer’s risk is crucial for developing effective prevention strategies.

The study’s authors concluded that recognizing the potential protective association between breast cancer treatment and Alzheimer’s may help enhance surveillance strategies for cognitive decline in this population. Though more research is needed, particularly studies with longer observation periods and more detailed treatment data, the findings offer a hopeful glimpse into how existing medical interventions might influence brain health.

Read more at nypost.com